Quick Answer
Grace Therapeutics, Inc. reported Earnings Per Share Diluted of $0.79 (loss) per share for the year ending 2025.
- Grace Therapeutics, Inc. showed an increase of +41.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Grace Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 23, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), Grace Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 192.6%.
- Historical annual values: Fiscal year 2025: $0.79 (loss) per share | Fiscal year 2024: $1.35 (loss) per share | Fiscal year 2023: $5.71 (loss) per share | Fiscal year 2022: $0.27 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: